Get the Stockscreener App
3.14
0.32%
0.01
After Hours:
3.13
-0.01
-0.32%
Esperion Therapeutics Inc stock is traded at $3.14, with a volume of 14.03M.
It is up +0.32% in the last 24 hours and up +0.96% over the past month.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
See More
Previous Close:
$3.13
Open:
$3.13
24h Volume:
14.03M
Relative Volume:
1.24
Market Cap:
$808.34M
Revenue:
$403.14M
Net Income/Loss:
$-22.68M
P/E Ratio:
-14.99
EPS:
-0.2095
Net Cash Flow:
$-13.09M
1W Performance:
+0.64%
1M Performance:
+0.96%
6M Performance:
-14.21%
1Y Performance:
+241.82%
1-Day Range:
$3.13
$3.14
1-Week Range:
$3.12
$3.14
52-Week Range:
$0.9149
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
3.14 | 805.76M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 48.00B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.08 | 40.34B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.70 | 39.10B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.39 | 32.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
540.05 | 23.12B | 3.17B | 1.29B | 1.01B | 27.09 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Esperion Therapeutics, Inc. 8-K Filing Details for May 28, 2026: Company Information, NASDAQ Listing, and Stock Option Plan Amendments - Minichart
Esperion (NASDAQ: ESPR) director receives 79,873-share stock award grant - Stock Titan
Esperion Therapeutics (ESPR) director receives 79,873-share stock award - Stock Titan
Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant - Stock Titan
Director at Esperion (NASDAQ: ESPR) receives 79,873-share stock grant - Stock Titan
Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award - Stock Titan
Esperion (NASDAQ: ESPR) investors approve 7M-share plan boost and board slate - Stock Titan
Esperion Therapeutics (ESPR) agrees to $3.16/share cash deal plus milestone CVRs - Stock Titan
ESPR News | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Trial tests cholesterol drug in kids with inherited high cholesterol - Stock Titan
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur - AD HOC NEWS
Epilogue On Esperion Therapeutics Stock (NASDAQ:ESPR) - Seeking Alpha
ETFs Investing in Esperion Therapeutics, Inc. Stocks - TradingView
Esperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97 - MSN
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization - Traders Union
Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent - AD HOC NEWS
ESPR Stock Surges 44% in a Month: Here's What You Need to Know - sharewise.com
Drugmaker Esperion gives new hires 260,000 stock units to join - Stock Titan
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - The Manila Times
Esperion Announces Two New Analyses Supporting Bempedoic - GlobeNewswire
New cholesterol data in kids and statin-intolerant adults at EAS 2026 - Stock Titan
Needham Maintains Esperion Therapeutics(ESPR.US) With Hold Rating - Moomoo
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
TradingKey - TradingKey
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk - The Globe and Mail
Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives - Sahm
Esperion Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR - Stock Titan
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Esperion Therapeutics Q1 2026 earnings preview - MSN
United StatesGoodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED - Mondaq
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
MSN Money - MSN
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH - Sahm
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Needham downgrades Esperion Therapeutics (ESPR) - MSN
BioPharma Credit to Finance Archimed's Purchase of Biotech Growth Trust's Esperion Therapeutics - Moomoo
Esperion to be acquired by ARCHIMED - The Pharma Letter
Esperion Therapeutics Cut to Hold From Buy by Needham - Moomoo
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com
What's Going On With Esperion Therapeutics Stock On Monday? - Benzinga
ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):